Agios Pharmaceuticals Has Announced Exclusive Worldwide License Agreement For Alnylam Pharmaceuticals' Preclinical siRNA Targeting TMPRSS6 For Polycythemia Vera; Agios Will Pay An Upfront Of $17.5M And Up To $130M In Milestone Payments
Author: Benzinga Newsdesk | August 03, 2023 06:49am